AstraZeneca PLC (AZN) income statement
NYSE · Healthcare · Drug Manufacturers - General · 96,100 employees · CEO Pascal Claude Roland Soriot
- Price
- $186.65 +7.02%
- Market cap
- $289B
- Enterprise value
- $316B
- Last report
- Q3 '26 filed 2026-10-30
- Next report
- 2027-02-09 EPS est. $2.41
AstraZeneca PLC (AZN) reported revenue of $16B for Q3 '26 (+5.3% year on year), operating income of $4.32B (27.0% of revenue) and net income of $3.08B. Over the last four quarters revenue was $62.2B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12B | $12.7B | $12.9B | $13.6B | $14.9B | $13.6B | $14.5B | $15.2B | $15.5B | $15.3B | $15.4B | $16B | |
| Cost of revenue | $2.31B | $2.22B | $2.18B | $3.08B | $2.73B | $2.24B | $2.47B | $2.8B | $3.12B | $2.68B | $2.52B | $4.06B | |
| Gross profit | $9.72B | $10.5B | $10.8B | $10.5B | $12.2B | $11.3B | $12B | $12.4B | $12.4B | $12.6B | $12.9B | $11.9B | |
| Research & development | $3.07B | $2.78B | $3.01B | $3.12B | $4.68B | $3.16B | $3.55B | $3.66B | $3.86B | $3.49B | $4.05B | $3.6B | |
| Sales & marketing | $145M | $135M | $132M | $145M | $143M | $135M | $143M | $148M | $153M | $141M | $145M | $0 | |
| General & administrative | $5.37B | $4.5B | $4.93B | $5.14B | $5.41B | $4.49B | $4.86B | $5.09B | $5.49B | $4.92B | $5.65B | $0 | |
| Other operating expenses | -$107M | -$67M | -$60M | -$25M | -$100M | -$113M | -$79M | -$89M | -$100M | -$189M | -$152M | $0 | |
| Operating expenses | $8.48B | $7.35B | $8.01B | $8.38B | $10.1B | $7.67B | $8.48B | $8.81B | $9.41B | $8.36B | $9.7B | $7.61B | |
| Operating income | $1.23B | $3.12B | $2.75B | $2.11B | $2.04B | $3.67B | $3.51B | $3.58B | $2.98B | $4.25B | $3.16B | $4.32B | |
| Interest income | $108M | $111M | $100M | $183M | $64M | $84M | $68M | $85M | $123M | $73M | $80M | $66.1M | |
| Interest expense | $445M | $413M | $443M | $457M | $429M | $349M | $439M | $434M | $472M | $393M | $435M | $471M | |
| Other non-operating income (gains on investments, FX ...) | -$108M | -$98M | -$94M | -$179M | -$59M | -$77M | -$58M | -$95M | -$123M | -$61M | -$70M | $0 | |
| Total non-operating income | -$337M | -$315M | -$349M | -$278M | -$370M | -$272M | -$381M | -$339M | -$349M | -$332M | -$365M | -$415M | |
| Income before tax | $897M | $2.8B | $2.4B | $1.83B | $1.67B | $3.4B | $3.13B | $3.24B | $2.63B | $3.91B | $2.8B | $3.91B | |
| Income tax | -$62M | $620M | $469M | $395M | $166M | $481M | $679M | $709M | $300M | $833M | $291M | $831M | |
| Net income | $960M | $2.18B | $1.93B | $1.43B | $1.5B | $2.92B | $2.45B | $2.53B | $2.33B | $3.08B | $2.51B | $3.08B | |
| EPS (basic) | $0.61 | $1.41 | $0.62 | $0.92 | $0.97 | $1.88 | $1.58 | $1.62 | $1.51 | $1.99 | $1.60 | $1.98 | |
| EPS (diluted) | $0.61 | $1.40 | $0.62 | $0.91 | $0.96 | $1.87 | $1.57 | $1.62 | $1.48 | $1.97 | $1.59 | $1.97 | |
| Shares (basic, weighted) | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.56B | 1.55B | 1.55B | 1.55B | 1.55B | |
| Shares (diluted, weighted) | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | |
| Depreciation & amortization | $1.36B | $1.26B | $1.28B | $1.82B | $714M | $1.28B | $1.39B | $1.55B | $1.53B | $1.37B | $1.93B | $1.58B | |
| EBITDA | $2.7B | $4.47B | $4.12B | $4.1B | $2.81B | $5.04B | $4.96B | $5.23B | $4.63B | $5.67B | $5.16B | $5.9B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23B | $22.5B | $22.1B | $24.4B | $26.6B | $37.4B | $44.4B | $45.8B | $54.1B | $58.7B | |
| Cost of revenue | $4.13B | $4.32B | $4.94B | $4.92B | $5.3B | $12.4B | $12.4B | $8.27B | $10.2B | $10.6B | |
| Gross profit | $18.9B | $18.1B | $17.2B | $19.5B | $21.3B | $25B | $32B | $37.5B | $43.9B | $48.1B | |
| Research & development | $5.89B | $5.76B | $5.93B | $6.06B | $5.99B | $9.74B | $9.76B | $10.9B | $13.6B | $14.2B | |
| Sales & marketing | $326M | $310M | $11B | $12B | $11.9B | $446M | $536M | $539M | $555M | $579M | |
| General & administrative | $9.41B | $10.2B | $0 | $0 | $0 | $15.1B | $17.4B | $17.7B | $19.7B | $19.9B | |
| Other operating expenses | -$1.66B | -$1.83B | -$3.15B | -$1.51B | -$1.73B | -$1.4B | $457M | $193M | $56M | -$381M | |
| Operating expenses | $14B | $14.5B | $13.8B | $16.5B | $16.2B | $23.9B | $28.2B | $29.4B | $33.9B | $34.4B | |
| Operating income | $4.9B | $3.68B | $3.39B | $2.92B | $5.16B | $1.06B | $3.76B | $8.19B | $10B | $13.7B | |
| Interest income | $59M | $109M | $138M | $165M | $83M | $43M | $81M | $301M | $345M | $360M | |
| Interest expense | $1.37B | $1.36B | $1.37B | $1.4B | $1.27B | $1.28B | $1.33B | $1.59B | $1.68B | $1.69B | |
| Other non-operating income (gains on investments, FX ...) | -$17M | $90M | $28M | -$26M | -$26M | $45M | -$74M | -$295M | -$370M | -$353M | |
| Total non-operating income | -$1.35B | -$1.45B | -$1.39B | -$1.38B | -$1.25B | -$1.32B | -$1.26B | -$1.29B | -$1.31B | -$1.34B | |
| Income before tax | $3.55B | $2.23B | $1.99B | $1.55B | $3.92B | -$265M | $2.5B | $6.9B | $8.69B | $12.4B | |
| Income tax | $146M | -$641M | -$57M | $321M | $772M | -$380M | -$792M | $938M | $1.65B | $2.17B | |
| Net income | $3.5B | $3B | $2.16B | $1.34B | $3.2B | $112M | $3.29B | $5.96B | $7.04B | $10.3B | |
| EPS (basic) | $2.77 | $2.37 | $1.70 | $1.03 | $2.44 | $0.08 | $2.12 | $3.81 | $4.54 | $6.60 | |
| EPS (diluted) | $2.76 | $2.37 | $1.70 | $1.03 | $2.44 | $0.08 | $2.11 | $3.81 | $4.50 | $6.54 | |
| Shares (basic, weighted) | 1.27B | 1.27B | 1.27B | 1.3B | 1.31B | 1.42B | 1.55B | 1.56B | 1.55B | 1.55B | |
| Shares (diluted, weighted) | 1.27B | 1.27B | 1.27B | 1.3B | 1.31B | 1.43B | 1.56B | 1.56B | 1.56B | 1.56B | |
| Depreciation & amortization | $2.36B | $3.04B | $3.75B | $3.76B | $2.9B | $4.1B | $5.25B | $4.93B | $5.07B | $5.73B | |
| EBITDA | $7.28B | $6.62B | $7.11B | $6.71B | $8.08B | $5.11B | $9.09B | $13.4B | $15.4B | $19.8B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates: Financial Modeling Prep.
Data as of 2026-11-01